BioCentury | Sep 13, 2019
Emerging Company Profile

Valo: adding tumor antigens to oncolytic viruses

...PeptiCRAd. The first of up to five programs will be a coated DNX-2440 for melanoma. DNX-2440...
...molecule OX-40 in Phase I testing for glioblastoma. Stein said Phase I testing of PeptiCRAd-enhanced DNX-2440...
Items per page:
1 - 1 of 1